Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392911 | 0.88 | GRIN2B (0.48) | GRIN2BCYP2D6CYP2C9CYP3A4KDM4E | |
| SCHEMBL5410680 | 0.86 | KDM4E (0.38) | GRIN2BCYP2D6CYP2C9CYP3A4KDM4E | |
| SCHEMBL5406578 | 0.84 | GPR119 (0.37) | GRIN2BCYP2D6CYP2C9CYP3A4KDM4E | |
| SCHEMBL5399454 | 0.77 | GRIN2B (0.47) | GRIN2BCYP2D6CYP2C9CYP3A4KDM4E | |
| SCHEMBL6421010 | 0.76 | GRIN2B (0.53) | GRIN2BCYP2D6CYP2C9CYP3A4KDM4E | |
| SCHEMBL5399467 | 0.75 | GRIN2B (0.58) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL5410050 | 0.75 | USP30 (0.36) | GRIN2BKDM4EPKMGPR119MAPT | |
| SCHEMBL5393303 | 0.74 | USP30 (0.34) | GRIN2BGPR119MAPT | |
| SCHEMBL5393341 | 0.73 | GPR119 (0.34) | GRIN2BCYP2D6CYP2C9GPR119 | |
| Trifluoroacetic Acid SCHEMBL6421335 | 0.73 | GRIN2B (0.49) | GRIN2BCYP2D6CYP2C9CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294627-B2 | Chemical compounds | ELI LILLY AND COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20040249151-A1 | Factor Xa inhibitors, useful in therapy of thrombotic disorders | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249151-A1 | Factor Xa inhibitors, useful in therapy of thrombotic disorders | F11, SERPINC1, F2 | GRIN2B 3372/4885CYP2D6 1854/4885CYP2C9 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.